Disclaimer

YOU ARE ABOUT TO ENTER AN ABBOTT COUNTRY OR REGION SPECIFIC WEBSITE.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions



DO YOU WISH TO CONTINUE AND ENTER THIS WEBSITE?

SJM-CV WEB-0718-0009

/content/bss/divisionalsites/livesites/reusable/cv-livesite/us/en/pages/home
30
CARDIOVASCULAR
hamburger
BACK
Technology

Technology

Unique Features: Shockguard Technology

For protection against inappropriate and unnecessary shocks, our Fortify Assura™ ICD utilizes expanded ShockGuard™ technology.

  • Approximately one-third of all ICD shocks are inappropriate.1
  • Reducing shocks correlates with increased quality of life.2
  • DecisionTx™ programming allows for better discrimination of arrhythmias, resulting in the most appropriate therapy for the patient.
  • Far Field MD™ morphology discrimination algorithm improves upon the use of near-field morphology analysis alone, further reducing inappropriate therapies.
  • Chamber Onset discrimination algorithm utilizes both atrial and ventricular interval information for rhythm diagnosis, determining which chamber is driving the arrhythmia.
  • SecureSense™ RV lead noise discrimination algorithm (Non-sustained SecureSense™ episodes) differentiates lead noise from true ventricular tachycardia (VT)/ventricular fibrillation (VF) episodes, providing the ability to automatically withhold tachycardia therapy in the presence of lead noise.

Patient Safety Enhancements

DynamicTx Over-current Detection Algorithm

DynamicTx™ over-current detection algorithm feature provides the opportunity for devices to deliver a shock, and possibly terminate a VT/VF episode, even in the presence of a compromised lead.

  • Checks for compromised vector integrity
  • Attempts to find a viable configuration to deliver high voltage therapy, while avoiding a problematic vector

TailoredTherapy Features

Our exclusive, customizable TailoredTherapy™ features allow you to individually adjust programming to meet the unique needs of each patient, delivering precise therapy for each patient, every time. These innovative features include:

  • DeFT Response™ technology
  • Complete capture confirmation
  • Automatic pacing outputs, periodically measured and adjusted, for optimal therapy delivery in every chamber of the heart

Building Comprehensive Cardiac Arrhythmia Management

The Fortify Assura ICD is part of our cardiac arrhythmia management portfolio. Our vision is to transform the treatment of cardiac arrhythmias by designing cost-saving technologies that improve therapy outcomes.

References

  1. Daubert, J. P., Zareba, W., Cannom, D. S., McNitt, S., Rosero, S. Z., Wang, P., … Moss, A. J., & MADIT II Investigators. (2008). Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: Frequency, mechanisms, predictors, and survival impact. Journal of the American College of Cardiology, 51(14), 1357 1365. https://dx.doi.org/10.1016/j.jacc.2007.09.073
  2. Sears, S. F., & Conti, J. B. (2002). Quality of life and psychological functioning of ICD patients. Heart, 87(5) , 488-493. https://dx.doi.org/10.1136/heart.87.5.488
  3. Data on file, bench testing data doc 60045162.
  4. Data on file, bench testing data doc 60045369.
Indications, Safety & Warnings

MAT-2205118 v1.0

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

False
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?

CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.

YESNO
accessibility
© 2021 Abbott. All Rights Reserved. Please read the Legal Notice for further details.

Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.

YESNO
accessibility

The following content is intended for Healthcare Professionals except for those in France. Some of the content is not in compliance with the French Advertising law N°2011-2012 dated 29th December 2011, article 34.



Si vous êtes un professionnel de santé exerçant en France ou dans les territoires Français, veuillez visiter notre site en français.



Do you want to continue? 

YesNo